Carbonate Patents (Class 424/715)
  • Patent number: 10058569
    Abstract: The invention relates to stable oral pharmaceutical compositions comprising lanthanum carbonate compounds and pharmaceutically acceptable excipients. The compositions of the present invention are formulated without the use of flow aids or lubricants. The compositions of the present invention have physical properties & flowability indicators comparable to that of the powders containing flow aids or lubricants and these compositions can be filled in sachets without any difficulty.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: August 28, 2018
    Assignee: LUPIN LIMITED
    Inventors: Makarand Krishnakumar Avachat, Nikhil P. Malewar, Anirudha B. Kute, Girish Purushottam Bang
  • Patent number: 9629806
    Abstract: Granules of racemic sodium ibuprofen dihydrate formed from components specified herein have very desirable properties and can be effectively used in conventional rotary press tableting equipment without operational difficulties often encountered in actual practice. Their preparation by a wet granulation process, the wet granule compositions, formulations adapted for preparation of solid dosage forms utilizing a rotary press, solid dosage forms, and methods of preparing solid dosage forms in a rotary press are also described.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 25, 2017
    Assignee: SI GROUP, INC.
    Inventor: Patrick C. Hu
  • Patent number: 9402808
    Abstract: The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: August 2, 2016
    Assignee: PANACEA BIOTEC LIMITED
    Inventors: Rajesh Jain, Sarabjit Singh, Paramjit Singh, Pirthi Pal Singh
  • Publication number: 20150104528
    Abstract: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventor: Matthew P. A. Fisher
  • Patent number: 8993003
    Abstract: The invention relates to a water-free oil-based composition which is liquid at 20° C./normal pressure and which contains (a) 2 to 90% by weight of at least one linear and/or branched dialkyl carbonate and (b) 2 to 95% by weight of at least one linear and/or branched alkane containing 8 to 40 carbon atoms and to its use in the cosmetics field.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: March 31, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Catherine Mitchell, Rolf Kawa, Ulrich Issberner, Achim Ansmann, Bettina Jackwerth
  • Patent number: 8980327
    Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 17, 2015
    Assignee: Shire LLC
    Inventors: David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
  • Patent number: 8974824
    Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 10, 2015
    Assignee: Mylan Laboratories Ltd.
    Inventors: Nagaraj Amminabavi, Indu Bhushan, Satish Kumar Jain, Subhash Gore, Gnanadeva Chalapathy Gudipati, Balakrishnan Chinnu, Subramanian Iyer, Manoj P Kumar, Rajesh S Gupta
  • Patent number: 8968796
    Abstract: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins and zinc (provided as Zn (II) EDTA alkali metal salt) mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is totally non-toxic in chemical nature and non-offensive in odor to others, so it can be used anywhere and at any time and can be swallowed after use.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: March 3, 2015
    Inventors: Plato Chun-Chih Lee, Arthur Joseph Dietrich
  • Publication number: 20150056296
    Abstract: [Problem] The objective of the present invention is, in a kit that is for preparing a carbon-dioxide-containing composition containing an oxygen-containing gel composition and a carbonate-containing gel composition, to provide a formulation technology enabling uniform and easy mixing, uniform generation of carbon dioxide, and the prevention of dripping down when applied to skin. [Solution] In the kit for preparing a carbon-dioxide-containing composition, by means of selecting the combination of a gel composition (1) containing a hydrophobically modified alkyl cellulose, an acid, and water, and a gel composition (II) containing sodium alginate, a carbonate, and water, it is possible to obtain uniform mixing by means of a two-agent mixing device, uniform generation of carbon dioxide, and the prevention of dripping down when applied to skin.
    Type: Application
    Filed: February 26, 2013
    Publication date: February 26, 2015
    Inventor: Masato Hiki
  • Patent number: 8962036
    Abstract: Disintegrable preparations of lanthanum carbonate prepared by co-precipitation, facilitating the manufacture of oral pharmaceutical dosage forms such as tablets, capsules, powders, granules, and sprinkles, and the use of such dosage forms to treat subjects with hyperphosphatemia are disclosed.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: February 24, 2015
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Andrea Blum Works, John Twist, Okey Noe
  • Publication number: 20150030693
    Abstract: An object of the present invention is to provide an antitumor aqueous solution and an anticancer agent, both of which can kill cancer cells while having virtually no effects on normal cells, and to provide methods for producing the antitumor aqueous solution and the anticancer agent. The method of the invention for producing an antitumor aqueous solution for killing cancer cells includes an aqueous solution preparation step of preparing an aqueous solution through addition, to water, of a solute containing at least one of disodium hydrogen phosphate (Na2HPO4), sodium hydrogen carbonate (NaHCO3), L-glutamine, L-histidine, and L-tyrosine disodium dihydrate (L-tyrosine.2Na.2H2O); and a plasma irradiation step of irradiating the aqueous solution with atmospheric pressure plasma generated in a plasma generation region by means of a plasma generator.
    Type: Application
    Filed: February 26, 2013
    Publication date: January 29, 2015
    Applicants: c/o NATONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, NU ECO ENGINEEERING CO., LTD.
    Inventors: Masaru Hori, Masaaki Mizuno, Fumitaka Kikkawa, Hiroaki Kajiyama, Fumi Utsumi, Kae Nakamura, Kenji Ishikawa, Keigo Takeda, Hiromasa Tanaka, Hiroyuki Kano
  • Publication number: 20150024070
    Abstract: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins, zinc and iron mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is all-natural, non-toxic and completely ingestible, so it may be used almost anywhere and at almost any time and can be swallowed after use.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 22, 2015
    Inventors: Plato Chun-Chih Lee, Arthur Joseph Dietrich
  • Publication number: 20150001066
    Abstract: A wipe for anti-microbial disinfecting includes a flexible substrate and an anti-microbial ion source integrated on the substrate. The flexible substrate is made entirely or in part of woven fiber cloth, non-woven fiber cloth, woven synthetic cloth, non-woven synthetic cloth, or natural fiber cloth. The anti-microbial ion source is configured to dissolve in an aqueous solution to form an anti-microbial solution. The flexible substrate is configured to absorb the anti-microbial solution for use in cleaning.
    Type: Application
    Filed: June 25, 2014
    Publication date: January 1, 2015
    Inventor: Ashok V. Joshi
  • Patent number: 8920715
    Abstract: An antimicrobial solution for disinfecting instruments in an automatic sterilization device, the solution comprising: a peracid reaction product formed in situ from combining a liquid acetyl donor with a solid source of peroxide, wherein the in situ reaction takes place in the sterilization device, along with a containment and delivery ampule for use in an automatic sterilization device, and methods for disinfecting a medical instrument employing the inventive antibacterial solution.
    Type: Grant
    Filed: August 7, 2006
    Date of Patent: December 30, 2014
    Assignee: Hemostasis, LLC
    Inventors: Keith Allen Roberts, Carl William Hahn, Gabriel P. Kern, Ryan A. Hoitink, Robert Orvin Crowder, John Henry Burban
  • Publication number: 20140377372
    Abstract: A cleaning compound for cleaning surfaces that includes at least one container, with each container including a peroxide and/or an alkaline reactant therein. The alkaline reactant is selected to raise the pH of the cleaning compound into the alkaline range when the peroxide and the alkaline reactant are mixed together. The cleaning compound may be a liquid or dry compound, which is applied to the surface to be cleaned.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Inventor: WILLIAM E. SPINDLER
  • Publication number: 20140348954
    Abstract: A nutraceutical preparation and/or food supplement and/or medical device product for the use in the treatment of gastric reflux including the association of glucomannan and an organic base, chitosan, and optionally one or more carbonates.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Applicant: DICOFARM S.P.A.
    Inventors: Laura MARTELLI, Mario MARTELLI, Maurizio ACRI, Piero FERRACCHIATI
  • Patent number: 8865227
    Abstract: Silver-containing particles, and methods of making silver-containing particles are disclosed.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: October 21, 2014
    Assignee: Smith & Nephew (Overseas) Limited
    Inventors: Nicholas Dunwoody, Zachary S. Wilson
  • Publication number: 20140271911
    Abstract: This invention is a pharmaceutical composition comprising of lithium as an active ingredient, to decrease intracellular calcium ion concentrations, and a beta-secretase inhibitor as an active ingredient, to reduce beta-secretase activity; for the treatment and prevention of disease, including disease characterized by the abnormal cleavage of amyloid precursor protein.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 18, 2014
    Inventor: James Wallace
  • Publication number: 20140255517
    Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing posttraumatic stress disorder comprising administering a pharmaceutical composition comprising effective amount of an angiotensin-converting enzyme inhibitor to a subject in need thereof. In certain embodiments, the angiotensin-converting enzyme inhibitor is administered in combination with an angiotensin receptor blocker.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Kerry J. Ressler, Paul J. Marvar
  • Publication number: 20140255495
    Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Inventor: Dale R. Bachwich
  • Patent number: 8828452
    Abstract: Methods for providing post-operative pain control or relief to a patient are disclosed. Methods include, for example, administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, in an area previously administered or containing a regional or local anesthetic in an amount sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: September 9, 2014
    Inventor: Glenn Abrahmsohn
  • Publication number: 20140234443
    Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.
    Type: Application
    Filed: March 10, 2014
    Publication date: August 21, 2014
    Applicant: Albany Molecular Research, Inc.
    Inventors: Peter R. GUZZO, David D. MANNING, William EARLEY
  • Patent number: 8808721
    Abstract: The present invention relates to compositions and methods for attracting bed bugs with novel attractants and new and improved methods to enable their use to attract, monitor or trap bed bugs for surveying, monitoring, mitigation and management purposes. Known mammal pheromones were discovered to be useful as bed bug kairomone attractants. A method of delivering non-volatile attractants by using the attractive heat source to heat and volatilize the attractants was discovered to be the optimal method to disseminate the kairomones. A new method of generating low levels of carbon dioxide is disclosed, and the combination of kairomones, carbon dioxide and heat is shown to attract bed bugs.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: August 19, 2014
    Assignee: SpringStar Inc.
    Inventors: Michael Gilbert Banfield, Elizabeth Joy Schaafsma
  • Publication number: 20140227198
    Abstract: Shelf stable compositions comprising olive extracts are described herein. The compositions include an olive extract comprising hydroxytyrosol, tyrosol, and oleuropein, wherein the weight ratio of hydroxytyrosol to oleuropein is 3:1 or less and the weight ratio of hydroxytyrosol to tyrosol is 2.85:1 or less. The compositions are stable for at least 12 months. Methods of using the shelf stable compositions are also described herein.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 14, 2014
    Applicant: GRADS Holdings LLLP
    Inventor: John Alkire
  • Patent number: 8778311
    Abstract: The present invention relates to an oral composition comprising, in an orally acceptable carrier, from about 0.1% to about 5% zinc oxide; and from about 0.1% to about 5% of a source of carbonate ions selected from alkali metal and ammonium carbonates and bicarbonates. The molar ratio of carbonate ion to zinc ion is from about 0.05:1 to about 1:1. The composition has good antiplaque efficacy and taste. Preferred compositions are toothpastes.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: July 15, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Meinrad Regner, Maurice Joseph Prendergast, Owen Thurlby
  • Publication number: 20140193526
    Abstract: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma. Formulations and methods of the invention are especially useful in treating neurological trauma, such as those caused by sports injuries and improvised explosive devices in combat.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 10, 2014
    Inventor: James Lome Henry
  • Publication number: 20140193528
    Abstract: Novel three-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Three-component formulations of the invention comprise biologically active forms of at least one neurosteroid, at least one anti-epileptic or anticonvulsant, and at least one lithium-containing or lithium-related compound. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by neurotrauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat.
    Type: Application
    Filed: September 4, 2013
    Publication date: July 10, 2014
    Inventor: James Lorne Henry
  • Publication number: 20140193523
    Abstract: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage.
    Type: Application
    Filed: January 6, 2014
    Publication date: July 10, 2014
    Inventor: James Lorne HENRY
  • Publication number: 20140193527
    Abstract: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma. Formulations and methods of the invention are especially useful in treating neurological trauma, such as those caused by sports injuries and improvised explosive devices in combat.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 10, 2014
    Inventor: James Lorne Henry
  • Publication number: 20140178503
    Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventors: Ronald C. Newbold, Chengzhi Zhang
  • Publication number: 20140171324
    Abstract: A composition of alkali carbonate peroxyhydrate in a quantity of 45 to 85% by weight relative to a total amount of the composition and an alkali hydrogen carbonate is provided for combating pathogenic germs and parasites in water of aquaculture, ponds, and aquariums; for destroying thread algae in water; for processing water. The addition of alkali hydrogen carbonate to alkali percarbonate peroxyhydrate stabilizes the alkali percarbonate peroxyhydrates relative to combustible materials. The alkali carbonate peroxyhydrate is preferably Na2CO3 and xH2O2.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 19, 2014
    Applicant: Söll GmbH
    Inventor: Thomas Willuweit
  • Publication number: 20140170200
    Abstract: Disclosed is pesticidal particulate composition of matter, the particles comprising active substances, which react upon contact inside a pest body, the reaction generating a gaseous product and/or heat which destroy the pest. Pesticidal preparations, methods and kits are also disclosed.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: ECOLOGIC TECHNOLOGIES LTD.
    Inventor: Ido OFEK
  • Patent number: 8747912
    Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: June 10, 2014
    Assignee: Isis Innovation Limited
    Inventor: Dermot Michael O'Hare
  • Patent number: 8709396
    Abstract: The invention is a method for attracting mosquitoes by producing a volatilized acid by combining an acid precursor with water to produce the humidified vapor acid attractant, preferably hydrogen chloride. The humidified volatilized acid can be further combined with carbon dioxide, or carbon dioxide can be simultaneously produced to attract mosquitoes. The acid precursor can be a hydrate of ferric chloride, such as ferric chloride hexahydrate. The acid precursor can be impregnated in a carrier, and can be combined with water through exposure to water vapor in the atmosphere, the intentional addition of water, or water produced by a chemical reaction.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: April 29, 2014
    Assignee: Premark FEG L.L.C.
    Inventors: Joel Tenney, Tom Isaac, William Ernst
  • Patent number: 8709500
    Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: April 29, 2014
    Assignee: Isis Innovation Limited
    Inventor: Dermot Michael O'Hare
  • Patent number: 8697132
    Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: April 15, 2014
    Assignee: Shire LLC
    Inventors: Roger Withington, David Pierce
  • Publication number: 20140037757
    Abstract: The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: February 6, 2014
    Inventors: Barbara Ehrlich, Sara Rockwell, Jennifer Benbow
  • Publication number: 20130337052
    Abstract: Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle.
    Type: Application
    Filed: September 24, 2012
    Publication date: December 19, 2013
    Inventors: Patricia Linert, Kenneth J. Ouimet
  • Publication number: 20130316022
    Abstract: The invention provides a method to enhance antimicrobial activity, e.g., in a mammal.
    Type: Application
    Filed: April 26, 2013
    Publication date: November 28, 2013
    Applicant: University of Iowa Research Foundation
    Inventors: Michael J. Welsh, Joseph Zabner
  • Publication number: 20130302438
    Abstract: A process for producing aqueous chlorous acid solution in which chlorous acid, which is safe for the human body, is easy to handle, and less generates chlorine dioxide, is yielded and used as a disinfectant for a pretreatment in food processing. To an aqueous sodium chlorate solution is added sulfuric acid or an aqueous solution thereof in such an amount and concentration that the pH of the aqueous solution can be kept at 2.3-3.4 to thereby react them and generate chloric acid. Subsequently, hydrogen peroxide is added to the chloric acid in an amount which is equal to or larger than the amount necessary for a reduction reaction to thereby yield chlorous acid. Any one of inorganic acids, inorganic acid salts, organic acids, and organic acid salts, or two or more thereof, or a combination or these is added to the aqueous solution containing chlorous acid yielded, whereby the chlorous and acid can be present for long and the pH of the aqueous solution is regulated to regulated to 3.2-7.0.
    Type: Application
    Filed: April 15, 2013
    Publication date: November 14, 2013
    Inventor: Hisataka Goda
  • Patent number: 8551535
    Abstract: Homeopathic compositions and formulations are disclosed. In one embodiment, compositions and formulations are disclosed that aid in weight loss and maintenance of a healthy weight. In another embodiment, methods are disclosed for producing homeopathic compositions and formulations. In still another embodiment, methods are disclosed for helping an individual lose weight.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: October 8, 2013
    Inventor: Sarah McCann
  • Publication number: 20130259875
    Abstract: Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
    Type: Application
    Filed: May 10, 2011
    Publication date: October 3, 2013
    Applicant: QUESTCOR PHARMACEUTICALS, INC.
    Inventor: Kathleen C. Somera-Molina
  • Patent number: 8545863
    Abstract: Controlling insects of the superfamily of the Psylloidea in horticultural and/or agricultural crops, by using bicarbonate and carbonate salts.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: October 1, 2013
    Assignee: Globachem
    Inventor: Koen Quaghebeur
  • Patent number: 8530560
    Abstract: Embodiments described include devices and methods for forming a porous polymer material. Devices disclosed and formed using the methods described include a spacer for spinal fusion, craniomaxillofacial (CMF) structures, and other structures for tissue implants.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 10, 2013
    Assignee: DePuy Synthes Products, LLC
    Inventors: Sean Hamilton Kerr, Ali Recber, Thomas Pepe, Dominique Messerli, Lawton Laurence, Ryan Walsh, Thomas Kueenzi, Brandon Randall
  • Publication number: 20130156869
    Abstract: The present invention provides the use of lithium compounds in micro-doses for the treatment of Alzheimer's disease. The results show that the administration of lithium in micro-doses provides a known not-toxic alternative to the elderly for slowing or stopping the progress of the disease and the progressive cognitive deterioration.
    Type: Application
    Filed: April 7, 2011
    Publication date: June 20, 2013
    Applicant: Funddacao Arnaldo Vieira de Carvalho
    Inventors: Marielza Andrade Nunes, Hudson de Sousa Buck
  • Patent number: 8440230
    Abstract: The present invention is related to a formulation based on micronized natural calcite mineral consisting of: A. mineral part which is characterized: (i) by the particle size with diameter smaller than 5 ?m, where the distribution of particle size is such that minimum of 10% of particles are with diameter under 900 nm, with total surface of particles greater than 3.2 m2/g, and with total porous volume greater than 0.012 cm3/g, and by composition: (ii) CaCO3, MgCO3, FeCO3, MnCO3, ZnCO3 and SiO2 in mixtures where CaCO3 is presented in amount from 10% to 99% of mineral part; and B. adjuvant selected from the group consisting of: wetting agent, drift-control agent at application by spraying, humic acid salt, amino-acids salts, complex of plant micro-nutrients, vitamin, plant hormone, nitrogen fertilizer, potassium salt, borate salt, molybdate salt, plant extract, chlorophyll, yeast extract, or mixture of these substances; where A. and B. form an aqueous suspension wherein percentage of A. and B.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: May 14, 2013
    Assignee: Mikro Mineral USA, Inc.
    Inventors: Antonio Lelas, Ivica Cepanec
  • Publication number: 20130108714
    Abstract: The present invention relates to a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods of treatment are disclosed herein.
    Type: Application
    Filed: January 18, 2011
    Publication date: May 2, 2013
    Applicant: SINOX PHARMA, INC.
    Inventor: Howard M. Alliger
  • Publication number: 20130052279
    Abstract: The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and metal ions. Reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of metal ions to target sites. It is advantageously useful in the pharmaceutical and dietetic fields.
    Type: Application
    Filed: March 24, 2011
    Publication date: February 28, 2013
    Applicant: MEDESIS PHARMA
    Inventor: Jean-Claude Maurel
  • Publication number: 20130039998
    Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.
    Type: Application
    Filed: December 23, 2009
    Publication date: February 14, 2013
    Applicants: UNIVERSITY OF WASHINGTON, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Daniel Fass, Stephen Haggarty, Edward Scolnick, Randall T. Moon, Travis L. Biechele, Nathan D. Camp
  • Publication number: 20130017263
    Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 17, 2013
    Applicant: OREXO AB
    Inventors: ANDERS PETTERSSON, CHRISTER NYSTROM, YVONNE HAKANSSON